Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety Study in Auto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nephrology, dialysis, transplantation dialysis, transplantation, 2018-04, Vol.33 (4), p.645-652
Hauptverfasser: Cornec-Le Gall, Emilie, Blais, Jaime D, Irazabal, Maria V, Devuyst, Olivier, Gansevoort, Ron T, Perrone, Ron D, Chapman, Arlene B, Czerwiec, Frank S, Ouyang, John, Heyer, Christina M, Senum, Sarah R, Le Meur, Yannick, Torres, Vicente E, Harris, Peter C
Format: Artikel
Sprache:eng
Schlagworte:
Immunology
Life Sciences
ORIGINAL ARTICLES
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (TEMPO3/4) trial. In the post hoc analysis, PKD1 and PKD2 were screened in 770 subjects and the PROPKD score was calculated in mutation-positive subjects (male: 1 point; hypertension
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfx188